← Back to all media
Reducing risk through expertise, diversification and a proven investment strategy
Biotechnology is a high-growth sector so it’s understandably alluring for many investors. Many, however, are put off by the perception that it is risky. Success in drug trials can lead to a company doubling its market cap overnight, but failure can lead to capitulation. The swings from fortune to failure can be brutal. So how can investors reap the benefits of the anticipated growth in the biotech market without unacceptably high risks?
Published on 30th September 2019